Eisai’s Alzheimer’s Pipeline Offers Combination Therapy Potential

Latest Leqembi Analyses Show Consistent Efficacy

 
• By Mandy Jackson
  
Generate a summary of this article
Listen to this article
Beta

Eisai is testing its anti-tau antibody in combination with the anti-amyloid therapy Leqembi, and earlier-stage programs targeting TrkA, EphA4 and TREM2 offer new approaches and combo potential.

Human brain research and memory loss as symbol of alzheimer's concept with missing pieces of the puzzle
Eisai continues to look for novel mechanisms to treat Alzheimer's disease • Source: Shutterstock

Eisai Co., Ltd. has a challenging task ahead in bringing its Biogen, Inc.-partnered amyloid protofibril-clearing antibody Leqembi (lecanemab) to Alzheimer’s patients in a market that is struggling to meet the testing and I.V. administration requirements for the medicine. However, that hasn’t stopped the company from investing in additional new medicines for the disease, including an anti-tau antibody and other novel treatments that could see use alone or in combination with Leqembi or other drugs.

Eisai continues to analyze results from the Phase III Clarity AD clinical trial that supported full approval by the US...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

  • Sciwind Eyes Differentiation For Ecnoglutide In Highly Competitive Arena

     
    • By Xu Hu

    Chinese firm Sciwind has revealed additional Phase III findings for its promising once-weekly GLP-1 agonist ecnoglutide, just one asset in a burgeoning Chinese sector that could see the emergence of new rivals to current global leaders in obesity and diabetes.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

     
    • By Xu Hu

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

  • Sponsored By:

    Nancy Tests SPARC-931-part

    The article discusses the impact of upcoming patent expirations in oncology biologics on biosimilar developers, highlighting the opportunities in Antibody-Drug Conjugates (ADCs) and Bispecific Antibodies (BsAbs). It explores the challenges posed by the structural complexities of these biologics, necessitating new bioanalytical tools and manufacturing processes. The evolving regulatory landscape, with contributions from EMA, FDA, and WHO, offers flexible pathways but also presents challenges. The article underscores the potential for biosimilars to generate significant cost savings and enhance patient access to cancer treatments over the next decade.

  • Fosun ALK/ROS1 Inhibitor Shows 1L Promise In Advanced NSCLC

    Interim results from the Phase III REMARK study presented at WCLC showed the Chinese company’s second-generation ALK/ROS1 inhibitor met its primary endpoint as a first-line therapy in ALK-positive advanced NSCLC.

More from R&D